Yves Levy

Summary

Country: France

Publications

  1. ncbi [Specific immunotherapy for HIV infection: objectives and limits]
    Yves Levy
    Service d'Immunologie Clinique, , , France
    Therapie 60:267-9. 2005
  2. ncbi Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group
    Y Levy
    Unité d Immunologie Clinique, Hopital Henri Mondor, Creteil, France
    Lancet 353:1923-9. 1999
  3. ncbi Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients
    Yves Levy
    Unité d Immunologie Clinique, Hopital Henri Mondor, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil Cedex, Paris, France
    AIDS 19:279-86. 2005
  4. ncbi Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals
    Yves Levy
    Hopital Henri Mondor, 51 av Mal de Lattre de Tassigny, 94010 Creteil, France
    AIDS 20:405-13. 2006
  5. ncbi AIDS progression is associated with the emergence of IL-17-producing cells early after simian immunodeficiency virus infection
    Laure Campillo-Gimenez
    Institut National de la Santé et de la Recherche Médicale U 955, Faculté de Médecine de Créteil, Hopital Henri Mondor, Creteil, France
    J Immunol 184:984-92. 2010
  6. ncbi Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment
    Yves Levy
    1INSERM U955, Universite Paris 12, and Assistance Publique Hôpitaux de Paris AP HP, Groupe Henri Mondor Albert Chenevier, Immunologie Clinique, Creteil, France
    J Clin Invest 119:997-1007. 2009
  7. ncbi Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study
    Cecile Goujard
    Service de Medecine Interne, Bicetre Hospital, AP HP, Le Kremlin Bicetre, Paris, France
    AIDS Res Hum Retroviruses 23:1105-13. 2007
  8. ncbi Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults
    Claire Rabian
    Laboratoire d Immunologie et d Histocompatibilité, St Louis Hospital, Paris, France
    Clin Infect Dis 50:1174-83. 2010
  9. ncbi Notch increases T/NK potential of human hematopoietic progenitors and inhibits B cell differentiation at a pro-B stage
    Clarisse Benne
    INSERM, Unite U955, Creteil, France
    Stem Cells 27:1676-85. 2009
  10. ncbi Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy
    Laurence Weiss
    Faculte de Medecine, Universite Paris Descartes, Assistance Publique Hopitaux de Paris AP HP, Hopital Europeen Georges Pompidou, Paris, France
    PLoS ONE 5:e11659. 2010

Detail Information

Publications33

  1. ncbi [Specific immunotherapy for HIV infection: objectives and limits]
    Yves Levy
    Service d'Immunologie Clinique, , , France
    Therapie 60:267-9. 2005
  2. ncbi Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group
    Y Levy
    Unité d Immunologie Clinique, Hopital Henri Mondor, Creteil, France
    Lancet 353:1923-9. 1999
    ..We did a randomised study to compare safety and efficacy of antiviral treatment alone or combined with various interleukin-2 regimens in HIV-1-infected patients...
  3. ncbi Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients
    Yves Levy
    Unité d Immunologie Clinique, Hopital Henri Mondor, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil Cedex, Paris, France
    AIDS 19:279-86. 2005
    ..Several lines of evidence suggest that the immune system may control HIV-1 replication, but that it could fail in the long term. Strategies aimed to elicit specific immune responses may enable patients to contain virus replication...
  4. ncbi Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals
    Yves Levy
    Hopital Henri Mondor, 51 av Mal de Lattre de Tassigny, 94010 Creteil, France
    AIDS 20:405-13. 2006
    ..The randomized ANRS 093 aimed at investigating whether a therapeutic immunization was effective in containing the long-term viral replication following discontinuation of antiretroviral drugs in patients...
  5. ncbi AIDS progression is associated with the emergence of IL-17-producing cells early after simian immunodeficiency virus infection
    Laure Campillo-Gimenez
    Institut National de la Santé et de la Recherche Médicale U 955, Faculté de Médecine de Créteil, Hopital Henri Mondor, Creteil, France
    J Immunol 184:984-92. 2010
    ..Altogether, these results demonstrate that IL-17-producing NKT are associated with the pathogenesis of SIV in RMs and suggest that TGF-beta and IL-18 play a role in their development...
  6. ncbi Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment
    Yves Levy
    1INSERM U955, Universite Paris 12, and Assistance Publique Hôpitaux de Paris AP HP, Groupe Henri Mondor Albert Chenevier, Immunologie Clinique, Creteil, France
    J Clin Invest 119:997-1007. 2009
    ..Therefore, patients may benefit from intermittent therapy with IL-7 in combination with c-ART...
  7. ncbi Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study
    Cecile Goujard
    Service de Medecine Interne, Bicetre Hospital, AP HP, Le Kremlin Bicetre, Paris, France
    AIDS Res Hum Retroviruses 23:1105-13. 2007
    ..Treatment interruption is safe in patients treated early after primary HIV infection. On the basis of this pilot study, HIV immunizations and interleukin-2 appear to have no supplementary benefit...
  8. ncbi Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults
    Claire Rabian
    Laboratoire d Immunologie et d Histocompatibilité, St Louis Hospital, Paris, France
    Clin Infect Dis 50:1174-83. 2010
    ..CD4 T cell responses specific to the diphtheria-derived carrier protein CRM(197) were evaluated...
  9. ncbi Notch increases T/NK potential of human hematopoietic progenitors and inhibits B cell differentiation at a pro-B stage
    Clarisse Benne
    INSERM, Unite U955, Creteil, France
    Stem Cells 27:1676-85. 2009
    ..These results may have implications both in physiology and for cell manipulation because they demonstrate a tight regulation of the fate of human progenitors by Notch signaling...
  10. ncbi Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy
    Laurence Weiss
    Faculte de Medecine, Universite Paris Descartes, Assistance Publique Hopitaux de Paris AP HP, Hopital Europeen Georges Pompidou, Paris, France
    PLoS ONE 5:e11659. 2010
    ..However, the insufficient increase in the proportion and/or the decrease in the absolute number of Tregs result in a failure to control immune activation following TI. TRIAL REGISTRATION: ClinicalTrials.gov NCT00118677...
  11. ncbi CD39/adenosine pathway is involved in AIDS progression
    Maria Nikolova
    INSERM, Unite U955, Creteil, France
    PLoS Pathog 7:e1002110. 2011
    ..Finally, in a genetic association study performed in three different cohorts, we identified a CD39 gene polymorphism that was associated with down-modulated CD39 expression and a slower progression to AIDS...
  12. ncbi Nonpathogenesis of simian immunodeficiency virus infection is associated with reduced inflammation and recruitment of plasmacytoid dendritic cells to lymph nodes, not to lack of an interferon type I response, during the acute phase
    Laure Campillo-Gimenez
    INSERM U841, Faculté Créteil Henri Mondor, 8 rue du General Sarrail, 94010 Creteil, France
    J Virol 84:1838-46. 2010
    ....
  13. ncbi Regulatory T cells differentially modulate the maturation and apoptosis of human CD8+ T-cell subsets
    Maria Nikolova
    INSERM U955, Creteil, France
    Blood 113:4556-65. 2009
    ..Thus, in the setting of a healthy immune system, Treg cells fine-tune the memory/effector cell balance and promote the accumulation of long-living memory cells in case of strong stimulation...
  14. ncbi Primary vasculitis of the central nervous system in patients infected with HIV-1 in the HAART era
    Giovanna Melica
    Service d immunologie clinique, CHU Henri Mondor, Creteil, France
    J Med Virol 81:578-81. 2009
    ..The prognosis of these patients remain poor despite HAART. These observations suggest that the vascular inflammatory process persists despite the control of viral load under HAART in patients with persistent immunosuppression...
  15. ncbi HIV-1 Nef protein expression in human CD34+ progenitors impairs the differentiation of an early T/NK cell precursor
    Céline Dorival
    INSERM U 841, Faculte de Medecine, Creteil, France
    Virology 377:207-15. 2008
    ..Altogether, these data demonstrate that Nef interferes with the differentiation of a primitive lymphoid human precursor with a T/NK potential...
  16. ncbi Therapeutic HIV vaccines: an update
    Yves Levy
    Service d immunologie clinique, Hopital Henri Mondor, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Curr HIV/AIDS Rep 2:5-9. 2005
    ..In clinical terms, this might allow patients to delay or to stop antiviral therapy and to minimize the duration of the exposition to antiviral drugs...
  17. ncbi Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults
    Philippe Lesprit
    Henri Mondor Hospital, Creteil, France bINSERM U593, Bordeaux, France
    AIDS 21:2425-34. 2007
    ....
  18. ncbi High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease
    Jean Gabarre
    Service d Hematologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France
    Haematologica 89:1100-8. 2004
    ....
  19. ncbi Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms
    Giovanna Melica
    Department of Clinical Immunology, Henri Mondor Hospital, Université Paris XII Creteil, Creteil, France
    AIDS 24:2130-3. 2010
    ..The median (range) maraviroc concentration in plasma was 347 ng/ml (123-2678). Four patients had CSF concentrations above the protein-adjusted inhibitory concentration (IC90) of 0.57 ng/ml (0.06-10.7) with a median of 102 ng/ml (35-173)...
  20. ncbi Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients
    Laurence Weiss
    Institut National de la Santé et de la Recherche Médicale U430, University of Paris V, France
    Blood 104:3249-56. 2004
    ..Taken together, our results suggest that persistence of HIV antigens might trigger the expansion of CD4(+)CD25(+) regulatory T cells, which might induce a tolerance to HIV in vivo...
  21. ncbi Early divergence in neutrophil apoptosis between pathogenic and nonpathogenic simian immunodeficiency virus infections of nonhuman primates
    Carole Elbim
    Faculte de Medecine, Service d Immunologie et d Hématologie, Assistance Publique Hopitaux de Paris, Centre Hospitalier Universitaire Xavier Bichat, Universite Paris 7 Denis Diderot, Paris, France
    J Immunol 181:8613-23. 2008
    ..This may account for the decline in PMN numbers that occurs during primary SIV infection in pathogenic SIV infection and may have important implications for subsequent viral replication and disease progression...
  22. ncbi Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect
    Samantha Brandler
    Unité Virus et Immunite, Institut Pasteur, URA CNRS 3015, Paris, France
    J Virol 84:5314-28. 2010
    ..Deciphering the immune responses to MVA in culture experiments will help in the design of innovative vaccine strategies...
  23. ncbi Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients
    Monia Ouederni
    Pediatric Hematology Immunology Unit, Assistance Publique Hopitaux de Paris AP HP, Necker Hospital, Paris, France
    Blood 118:5108-18. 2011
    ..RFXANK deficiency is a severe, often fatal CID for which HSCT is the only curative treatment. However, some patients may survive for relatively long periods if multiple prophylactic measures are implemented...
  24. ncbi [Cytokine therapies in HIV infection]
    Yves Levy
    Service d immunologie clinique, Hopital Henri Mondor, 51, Avenue du Marechal de Lattre de Tassigny, 94010 Creteil Cedex, France
    Med Sci (Paris) 22:751-4. 2006
    ..Although no data in human are still available, recent studies provide arguments to assess this cytokine in HIV infection. Phase I studies are ongoing or planned...
  25. ncbi Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1
    Anne Sophie Lascaux
    Department of Clinical Immunology, Hopital Henri Mondor, Creteil, France
    J Med Virol 84:194-7. 2012
    ..These patients were treated successfully with topical 5% imiquimod. Imiquimod treatment also appeared to delay the time to recurrence of HSV lesions...
  26. ncbi Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial
    Yves Levy
    Unit of Clinical Immunology, Hospital Henri Mondor, , , France
    AIDS 17:343-51. 2003
    ..01). CONCLUSIONS: The combination of antiviral drugs and IL-2 induced a greater expansion and function of CD4 T cells than antiretroviral drugs alone...
  27. ncbi Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02)
    Sophie Limou
    Conservatoire National des Arts et Metiers, Universite Paris 7, Paris, France
    J Infect Dis 199:419-26. 2009
    ..The present study, the first GWAS of HIV-1 nonprogressors, underscores the potential for some HLA genes to control disease progression soon after infection...
  28. ncbi Short exposure to Notch ligand Delta-4 is sufficient to induce T-cell differentiation program and to increase the T cell potential of primary human CD34+ cells
    Nathalie Lefort
    INSERM U 421, Faculte de Medecine, Creteil, France
    Exp Hematol 34:1720-9. 2006
    ..The Notch pathway plays a key role in cell fate choices and in T-cell development. The goal of our study was to evaluate whether a short in vitro stimulation of the Notch pathway may alter human progenitor cell behavior...
  29. ncbi Perspectives on interleukin-7 therapy in HIV infection
    Jean Daniel Lelievre
    Service d immunologie clinique, Hopital Henri Mondor, Universite Paris, Creteil, France
    Curr Opin HIV AIDS 2:228-33. 2007
    ..Because of its pleiotropic effects on developing and mature T cells, interleukin-7 may help to restore immune function during HIV infection...
  30. ncbi Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy
    Constance Delaugerre
    University Paris Descartes, EA 3620, Virology Department, Necker Hospital AP HP, Paris, France
    Antimicrob Agents Chemother 53:2934-9. 2009
    ..The mutation L76V may be considered in further studies of lopinavir resistance...
  31. ncbi Genomewide association study of a rapid progression cohort identifies new susceptibility alleles for AIDS (ANRS Genomewide Association Study 03)
    Sigrid Le Clerc
    Conservatoire National des Arts et Metiers, Paris, France
    J Infect Dis 200:1194-201. 2009
    ..The discovery of genetic factors that predispose individuals to rapid progression to AIDS should also reveal new insights into the molecular etiology of the pathology...
  32. ncbi Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy
    Richard T Davey
    National Institutes of Health, National Institute of Allergy and Infectious Disease, Bethesda, MD 20892, USA
    J Interferon Cytokine Res 28:89-100. 2008
    ..Bay 50-4798 was generally well tolerated across the dose range tested, but a lack of potent, sustained immunologic activity suggests that further optimization of dose and schedule will be necessary...
  33. ncbi CD4 regulation in human lymphoid non-T-cells: a role for the silencer element
    Enguerran Mouly
    Université Pierre et Marie Curie CNRS UMR 7087, Groupe Hospitalier Pitie Salpetriere, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    Mol Immunol 44:267-75. 2007
    ..Collectively, our results suggest that beyond its well-characterized function in T-cells, the CD4 silencer also regulates CD4 gene expression in human lymphoid non-T-cells...